Table 2.
PSC patients and controls enrolled in the previous protocol (IRB #670-02)
| Variable | PSC patients | Controls |
|---|---|---|
| n | 1174 | 650 |
| Age (yrs)a, median (IQR) | 51.6 (36.6–61.6) | 61.3 (53.9–68.1) |
| Sex, n (%) male | 733 (62.4) | 177 (27.2) |
| Race, n (%) Caucasian | 1087 (92.6) | 646 (99.4) |
| Available Specimens, n (%) of participants [total # of aliquots] | ||
| Genomic DNA / BC | 1166 (99.3) [3,316] | 624 (96.0) [1,723] |
| Plasma | 1117 (95.1) [5,821] | 635 (97.7) [2,100] |
| Serum | 719 (61.2) [1,705] | 540 (83.1) [1,229] |
| PBMC | 1091 (92.9) [2,743] | 607 (93.4) [1,120] |
| Stool | 95 (8.1) [185] | not collected |
| Age at PSC dx (yrs), median (IQR) | 40.6 (29.0-52.1) | na |
| PSC duration (yrs)a, median (IQR) | 6.2 (2.3–12.9) | na |
| IBD Type, n (%) of patients | ||
| Ulcerative colitis | 728 (62.4) | na |
| Crohn’s Disease | 119 (10.2) | |
| Indeterminate IBD | 54 (4.6) | |
| No IBD | 266 (22.8) | |
| Status unknown | 7 | |
| Clinical follow-upb, n (%) of patients | ||
| None | 564 (48.0) | na |
| 0–3 Years | 180 (15.3) | |
| 3–6 Years | 207 (17.6) | |
| 6 + Years | 223 (19.0) | |
| Liver Transplant, n (%) of patients | ||
| Prior to enrollment | 243 (20.7) | na |
| In follow-up | 74 (6.3) | |
| No transplant | 857 (73.0) | |
| Advanced Diseasec, n (%) of patients | ||
| Prior to enrollment | 366 (31.2) | na |
| In follow-up | 107 (9.1) | |
| No advanced disease | 701 (59.7) | |
| Hepatobiliary Cancerd, n (%) of patients | ||
| Prior to enrollment | 76 (6.5) | na |
| In follow-up | 50 (4.3) | |
| No hepatobiliary cancer | 1048 (89.3) | |
na, not applicable; BC, buffy coat; PBMC, peripheral blood mononuclear cells; IBD, inflammatory bowel disease
aAt time of blood sample collection
bClinical follow-up post first blood sample collection performed under IRB#670-02
cAdvanced disease defined as having one or more of the following: liver transplant, cirrhosis determination or hepatic decompensation event
dHepatobiliary cancer defined as having one or more of the following: cholangiocarcinoma, hepatocellular carcinoma or gallbladder cancer